The goal of this study is to see if the drug balstilimab is safe and effective in participants with relapsed/refractory lymphomas.
Participants will receive balstilimab every 3 weeks and their outcomes will be assessed periodically.
Voluntarily agree to participate by giving written informed consent
≥ 18 years of age
Have a histologically confirmed diagnosis of a relapsed/refractory classical Hodgkin lymphoma (cHL) or primary mediastinal B-cell lymphoma (PMBCL) for which no standard therapy is available or standard therapy has failed or the patient does not have access to it.
Has a life expectancy of at least 3 months and an ECOG performance status of ≤1 as determined by study Investigator
Received systemic cytotoxic chemotherapy within 3 weeks before initiation of study treatment
Received biological therapy or investigational therapy within 4 weeks or 5 circulating halve-lives, whichever is shorter
Received small molecule/tyrosine kinase inhibitors within 2 weeks or 5 circulating half-lives, whichever is shorter
Received radiation therapy within 3 weeks before initiation of study treatment, except for palliative radiation therapy, which can be received 2 weeks prior to initiation of study treatment
Immune Oncology Research Institute
Lead sponsor
Agenus Inc.
Collaborator